Chronic hepatitis C in minority populations

Current Hepatitis Reports

Volumn 7, Issue 4, 2008, Pages 158-163

  Rodríguez Torres, Maribel ^a  

^a Fundacion de Investigacion de Diego   (Puerto Rico)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HLA DQB1 ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 2; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; TELAPREVIR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VIRUS RNA;

ASIAN; CAUCASIAN; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; ETHNIC DIFFERENCE; EVIDENCE BASED MEDICINE; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HEPATITIS C; HEPATITIS C VIRUS; HEREDITY; HISPANIC; HUMAN; IMMUNE RESPONSE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MINORITY GROUP; MORTALITY; NEGRO; PATIENT EDUCATION; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 63149173696     PISSN: 15403416     EISSN: 15410706     Source Type: Journal    
DOI: 10.1007/s11901-008-0031-1     Document Type: Review

References (30)

1. Rawls RA, Vega KJ: Viral hepatitis in minority America. J Clin Gastroenterol 2005, 39: 144-151.
2. Rustgi VK: The epidemiology of hepatitis C infection in the United States. J Gastroenterol 2007, 42: 513-521.
3. Wise M, Bialek S, Finelli L, et al.: Changing trends in hepatitis C-related mortality in the United States, 1995-2004. Hepatology 2008, 47: 1128-1135.
4. Lepe R, Layden-Almer JE, Layden TJ, Cotler S: Ethnic differences in the presentation of chronic hepatitis C. J Viral Hepat 2006, 13: 116-120.
5. Rodríguez-Torres M, Rios-Bedoya CF, Rodriguez-Orengo J, et al.: Progression to cirrhosis in Latinos with chronic hepatitis C: differences in Puerto Ricans with and without human immunodeficiency virus coinfection and along gender. J Clin Gastroenterol 2006, 40: 358-366.
6. Wiley TE, Brown J, Chan JL: Hepatitis C infection in African Americans: its natural history and histological progression. Am J Gastroenterol 2002, 97: 700-706.
7. D'souza R, Glynn MJ, Ushiro-Lumb I, et al.: Prevalence of hepatitis C-related cirrhosis in elderly Asian patients infected in childhood. Clin Gastroenterol Hepatol 2005, 3: 910-917.
8. Missiha S, Heathcote J, Arenovich T, Khan K: Impact of Asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C. Am J Gastroenterol 2007, 102: 2181-2188.
9. Nguyen MH, Trinh HN, Garcia R, et al.: Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin. Am J Gastroenterol 2008, 103: 1131-1135.
10. Lee H, Choi MS, Paik SW, et al.: Peginterferon alfa-2a plus ribavirin for initial treatment of chronic hepatitis C in Korea [in Korean]. Korean J Hepatol 2006, 12: 31-40.
11. McHutchison JG, Poynard T, Pianko S, et al.: The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. Gastroenterology 2000, 119: 1317-1323.
12. Muir AJ, Bornstein JD, Killenberg PG: Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004, 350: 2265-2271.
13. Jacobson IM, Brown RS Jr, McCone J, et al.: Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. Hepatology 2007, 46: 982-990.
14. Jeffers LJ: Treating hepatitis C in African Americans. Liver Int 2007, 27: 313-322.
15. Gaglio PJ, Rodríguez-Torres M, Herring R, et al.: Racial differences in response rates to consensus interferon in HCV infected patients naive to previous therapy. J Clin Gastroenterol 2004, 38: 599-604.
16. Hepburn MJ, Hepburn LM, Cantu NS, et al.: Differences in treatment outcome for hepatitis C among ethnic groups. Am J Med 2004, 117: 163-168.
17. Rodríguez-Torres M, Jeffers LJ, Sheikh, MY, et al.: Virologic responses to peginterferon alfa-2a/ribavirin in treatment-naïve Latino vs non-Latino Caucasians infected with HCV genotype 1: The LATINO study. Paper presented at Digestive Disease Week. San Diego, CA; May 17-22, 2008.
18. Hsu CS, Liu CJ, Lai MY, et al.: Early viral kinetics during treatment of chronic hepatitis C virus infection with pegylated interferon alpha plus ribavirin in Taiwan. Intervirology 2007, 50: 310-315.
19. Kimball P, Elswick RK, Shiffman M: Ethnicity and cytokine production gauge response of patients with hepatitis C to interferon-alpha therapy. J Med Virol 2001, 65: 510-516.
20. Thio CL, Thomas DL, Goedert JJ, et al.: Racial differences in HLA class II associations with hepatitis C virus outcomes. J Infect Dis 2001, 184: 16-21.
21. Azocar J, Clavijo OP, Yunis EJ: MHC class II genes in HCV viral clearance of hepatitis C infected Hispanic patients. Hum Immunol 2003, 64: 99-102.
22. Romero-Gomez M: Hepatitis C anS insulin resistance: steatosis, fibrosis and non-response. Rev Esp Enferm Dig 2006, 98: 605-615.
23. Di Bisceglie AM, Lyra AC, Schwartz M, et al.: Hepatitis C-related hepatocellular carcinoma in the United States: Influence of ethnic status. Am J Gastroenterol 2003, 98: 2060-2063.
24. Estrada AL: Health disparities among African-American and Hispanic drug injectors - HIV, AIDS, hepatitis B virus and hepatitis C virus: A review. AIDS 2005, 19(Suppl 3): S47-S52.
25. Schackman BR, Teixeira PA, Beeder AB: Offers of hepatitis C care do not lead to treatment. J Urban Health 2007, 84: 455-458.
26. Butt AA, Justice AC, Skanderson M, et al.: Rate and predictors of treatment prescription for hepatitis C. Gut 2007, 56: 385-389.
27. Gupta K, Romney D, Briggs M, Benker K: Effects of a brief educational program on knowledge and willingness to accept treatment among patients with hepatitis C at inner-city hospitals. J Community Health 2007, 32: 221-230.
28. Rodríguez-Torres M: Chronic hepatitis C in the Latino population. Curr Hepat Rep 2008, 7: 106-112.
29. Fried M, Jensen D, Rodríguez-Torres M, et al.: Improved outcomes in hepatitis C patients with difficult to treat characteristics: randomized study of higher doses of peginterferon-2a and ribavirin: Hepatology, 2008 June 9 [Epub ahead of print].
30. Ferenci P, Fried MW, Shiffman ML, et al.: Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005, 43: 425-433.